Ryo Kubota

Chairman, President, and Chief Executive Officer
Acucela Inc.


Ryo Kubota

Ryo Kubota is Chairman, President, and Chief Executive Officer of Acucela Inc. Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases affecting millions of individuals worldwide.

Prior to founding Acucela in 2002, Dr. Kubota worked in the ophthalmology field, including serving as a faculty member at both Keio University and the University of Washington School of Medicine. He holds an MD and a PhD in medicine from Keio University. Dr. Kubota is board certified in ophthalmology by the Japanese Ophthalmological Society and is a member of the American Academy of Ophthalmology and the American Chamber of Commerce in Japan. He has been a director of the Japan-America Society of the State of Washington since 2008 and an advisor to the Japanese Institute for Global Health since 2013.

In the course of his work at Keio, Dr. Kubota discovered a glaucoma gene, myocilin, which earned him the Suda Award. He has completed the Harvard Business School Executive Education leadership and strategy program and was selected as one of the Nikkei Business 100, Nikkei Business Magazine’s inaugural list of the most influential people in Japan’s future. He was also selected as one of the most inspiring people in the life-science industry by PharmaVOICE.

This site uses cookies. Please read our Privacy Policy to learn how and why we use cookies.